Patents by Inventor Rajesh Ramchandra Walavalkar

Rajesh Ramchandra Walavalkar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160251342
    Abstract: The present invention concern towards the prodrug of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-morpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, rivaroxaban per se; processes for their preparation, and the application in treatment and/or prophylaxis of diseases, especially of thromboembolic disorders. The prodrug of compound formula (B) is chemically designated as 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl} methyl) thiophene-2-carboxamide.
    Type: Application
    Filed: May 9, 2016
    Publication date: September 1, 2016
    Inventors: NITIN SHARADCHANDRA PRADHAN, NILESH SUDHIR PATIL, RAJESH RAMCHANDRA WALAVALKAR, NILESH SUBHASH KULKARNI, SANDIP BABANRAO PAWAR, TARAK SAMBHAJI PAWAR
  • Patent number: 9394292
    Abstract: This invention relates to novel intermediate, formula (A) for rivaroxaban and process for the preparation thereof. Further it extends to the process for preparation of rivaroxaban by using the said novel intermediate, by treating with 5-chlorothiophene carbonyl chloride to form the rivaroxaban derivatives of formula (B). The obtained formula (B) further treated with acid to form rivaroxaban.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: July 19, 2016
    Assignee: WANBURY LTD.
    Inventors: Nitin Sharadchandra Pradhan, Nilesh Sudhir Patil, Rajesh Ramchandra Walavalkar, Nilesh Subhas Kulkarni, Sandip Babanrao Pawar, Tarak Sambhaji Pawar
  • Patent number: 9359341
    Abstract: The present invention relates to the prodrug of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-morpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, rivaroxaban per se; processes for their preparation, and the application in treatment and/or prophylaxis of diseases, especially of thromboembolic disorders. The prodrug of a compound of formula (B) is chemically designated as 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: June 7, 2016
    Assignee: WANBURY LTD.
    Inventors: Nitin Sharadchandra Pradhan, Nilesh Sudhir Patil, Rajesh Ramchandra Walavalkar, Nilesh Subhas Kulkarni, Sandip Babanrao Pawar, Tarak Sambhaji Pawar
  • Publication number: 20150299175
    Abstract: This invention relates to novel intermediate, formula (A) for rivaroxaban and process for the preparation thereof. Further it extends to the process for preparation of rivaroxaban by using the said novel intermediate, by treating with 5-chlorothiophene carbonyl chloride to form the rivaroxaban derivatives of formula (B). The obtained formula (B) further treated with acid to form rivaroxaban.
    Type: Application
    Filed: December 24, 2013
    Publication date: October 22, 2015
    Inventors: Nitin Sharadchandra Pradhan, Nilesh Sudhir Patil, Rajesh Ramchandra Walavalkar, Nilesh Subhas Kulkarni, Sandip Babanrao Pawar, Tarak Sambhaji Pawar
  • Publication number: 20150259333
    Abstract: The present invention concern towards the prodrug of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-morpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide, rivaroxaban per se; processes for their preparation, and the application in treatment and/or prophylaxis of diseases, especially of thromboembolic disorders. The prodrug of compound formula (B) is chemically designated as 5-chloro-N-formyl-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide.
    Type: Application
    Filed: December 24, 2013
    Publication date: September 17, 2015
    Applicant: WANBURY LTD.
    Inventors: Nitin Sharadchandra Pradhan, Nilesh Sudhir Patil, Rajesh Ramchandra Walavalkar, Nilesh Subhas Kulkarni, Sandip Babanrao Pawar, Tarak Sambhaji Pawar